The Second CAR-T Therapy in China Applied for Marketing

On June 30, according to the official website of CDE, the marketing application of a CAR-T therapy, JWCAR029 by JW Therapeutics was accepted by CDE, which makes it one step closer to the marketing of JW Therapeutic's first CAR-T product, also meaning the second CAR-T therapies in China are applied for production.

JWCAR029 is a CAR-T product independently developed by JW Therapeutics, based on JCAR017 of Juno Company in the United States.

At present, no CAR-T therapy has been approved in China. However, according to the Insight Database, many companies have begun to lay out. Among them, Fosun Kite's FKC876 is in the fastest progress, which was applied for markting in February this year. In addition, Tisagenlecleucel of Novartis is currently in Phase III clinical trials.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.